Dihexa for CTE (Chronic Traumatic Encephalopathy): Boston University 2026 Dementia Study, UK Rugby Litigation, Tau, BBB Leakage & the 2026 UK Review

Chronic traumatic encephalopathy (CTE) moved out of the sports pages and into mainstream neurology in 2026. In January 2026 the Boston University CTE Center published the largest brain-bank analysis of its kind in Alzheimer’s & Dementia: across 614 donors exposed to repetitive head impacts, those with the most advanced form of CTE had a four-times higher odds of dementia — comparable in magnitude to advanced Alzheimer’s pathology — supporting the argument that CTE should be recognised as a distinct cause of dementia in its own right. Four months later, the same group reported that the proposed traumatic encephalopathy syndrome (TES) clinical criteria correctly identified only 24% of autopsy-confirmed CTE cases, raising serious concerns about misdiagnosis in athletes and veterans. In the United Kingdom, more than 1,100 former rugby union and rugby league players — including members of England’s 2003 World Cup-winning squad — are pursuing a group action against World Rugby, the RFU, the WRU and the RFL over alleged brain-injury negligence, with the case next scheduled for review in March 2026. Against this backdrop, the question keeps surfacing: does the synaptogenic, HGF/c-Met-activating peptide Dihexa have anything to offer the CTE population? This rigorous 2026 UK review covers what is actually known, what is speculation, and where the evidence is genuinely absent. Readers may also want to read the closely-related Dihexa for TBI, Concussion & Stroke Recovery review, the Dihexa for Stroke Recovery & PSCI review and the Dihexa for PTSD & Complex PTSD review — the three sister neurorepair articles that share the underlying biology.

What Is Chronic Traumatic Encephalopathy? The 2026 Definitional Landscape

Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease associated with a history of substantial exposure to repetitive head impacts (RHI), including subconcussive impacts that produce no immediate symptoms. The condition has historically gone under several names — dementia pugilistica, punch-drunk syndrome, traumatic encephalopathy — reflecting its long-established but poorly understood association with boxing. The modern CTE concept, formalised by the Boston University CTE Center from around 2008, broadened the spectrum to include American football, ice hockey, soccer (heading), rugby union and rugby league, mixed martial arts, wrestling, military blast exposure, and survivors of long-term interpersonal violence.

In 2021 a US National Institute of Neurological Disorders and Stroke (NINDS) consensus established uniform neuropathological diagnostic criteria, updated by McKee et al. (2023). The defining pathological lesion is a perivascular accumulation of hyperphosphorylated tau (p-tau) in neurons and astrocytes, located at the depths of cortical sulci, particularly in frontal and temporal cortex. This perivascular, sulcal-depth distribution distinguishes CTE tau from the diffuse cortical tau of Alzheimer’s disease (AD), the pretangle tau of normal ageing, the four-repeat (4R) tau of progressive supranuclear palsy (PSP), and the 3R tau of Pick’s disease / FTLD-tau.

Two crucial 2026 publications reshape how clinicians should think about CTE:

The January 2026 Boston University 614-Donor Study

In January 2026, Alosco and colleagues at the Boston University CTE Center published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association the largest clinicopathological study of its kind. The cohort of 614 brain donors — primarily contact-sport athletes — was stratified into 366 donors with CTE alone (no other progressive brain disease) and 248 donors without CTE. The headline finding: those with the most advanced (high-stage) form of CTE had a four-times increased odds of dementia, comparable to the strength of association between dementia and advanced Alzheimer’s pathology, which remains the leading cause of dementia. The authors explicitly argue this means CTE should be recognised as a new, distinct cause of dementia in its own right and counters recent contrarian claims that CTE has no genuine clinical correlate. The study was supported by the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the US Department of Veterans Affairs, and the Nick and Lynn Buoniconti Foundation.

The May 2026 TES 24% Sensitivity Finding

If CTE is now a recognised dementia, the next question is: how do we identify it during life? The current research construct is traumatic encephalopathy syndrome (TES) — a clinical phenotype of progressive cognitive impairment plus neurobehavioural dysregulation in someone with substantial RHI exposure. A May 2026 Boston University paper assessed the proposed clinical TES criteria against autopsy-confirmed CTE. The criteria identified only 24% of cases with confirmed CTE pathology, while also misclassifying many people without the disease. The authors warned that widespread clinical adoption could lead to misdiagnosis and unintended mental-health consequences — the population most at risk of being told they have CTE, and the population at the highest baseline suicide and behavioural risk, are the same population (athletes and veterans). This evidential gap is the central reason that no rigorous CTE treatment trial — for Dihexa or anything else — can yet be designed: without an in-vivo case definition, you cannot enrich a trial population, you cannot measure response, and you cannot stratify by stage.

The January 2020 Concussion Legacy Foundation Fact Sheet (updated January 2026) remains the standard public-facing summary, and is regularly updated.

Repetitive Head Impacts: The Causal Frame

The current consensus is that CTE is caused by cumulative exposure to repetitive head impacts, not by any single concussive event. The Glasgow / Boston / Sydney rugby brain-bank study (Stewart et al., 2023) found that CTE risk in 31 former rugby union players whose brains were donated for research correlated with length of playing career, with CTE present in around 68% of donors, in both amateur and elite players. The 2017 Boston University NFL paper reported CTE in 99% of 111 examined NFL players. Both studies are subject to severe ascertainment bias (donors are usually symptomatic at end of life) and do not establish population prevalence.

The key biological insight is the role of sub-concussive exposure — routine head contact that does not produce symptoms but does produce measurable axonal stretch, brief blood-brain barrier opening, microglial activation, and accumulation of small foci of perivascular p-tau. Each individual impact is sub-clinical; the integrated exposure across thousands of impacts over a multi-decade career is what appears to matter.

Exposure cohorts of interest in 2026 include:

• American football: the longest-studied exposure, with the most autopsy-confirmed cases.
• Rugby union and rugby league: UK and Australasian focus, with the Glasgow/Sydney/Boston studies cited above, the Imperial College London midlife rugby study suggesting elevated long-term risk, and the active UK group litigation.
• Soccer (football, association): heading the ball is the suspected exposure. The 2019 FIELD study (Mackay et al.) reported a 3.5× higher dementia mortality in former professional Scottish footballers vs matched controls. The English FA introduced graduated under-12s heading limits from 2020.
• Boxing: dementia pugilistica — the original CTE syndrome — remains a recognised entity.
• Ice hockey: several high-profile autopsy-confirmed cases.
• Mixed martial arts: short careers but very high impact density.
• Military blast exposure: recognised as a distinct RHI pathway with overlapping but not identical pathology; the US Department of Veterans Affairs / DoD LIMBIC-CENC programme is the principal evidence base.
• Survivors of long-term intimate-partner violence: an under-studied but biologically plausible cohort.

The clinical phenotype that develops in CTE is biphasic. Early phase (typically late 20s to 40s) is dominated by mood and behavioural change — depression, irritability, impulsivity, aggression, substance misuse, and suicidality — sometimes called frontal-temporal phenotype CTE. Late phase (50s onwards) is dominated by progressive cognitive decline, particularly memory and executive function, often indistinguishable clinically from Alzheimer’s dementia or behavioural-variant frontotemporal dementia. The Boston University 2026 dementia study addresses this late phase.

CTE Pathology: Why It Matters for Any Putative Therapy

The cellular and molecular pathology of CTE is the framework in which any candidate therapy — Dihexa or otherwise — must be evaluated. The dominant features are:

1. Perivascular Hyperphosphorylated Tau (the Defining Lesion)

The cardinal lesion is hyperphosphorylated 3R+4R tau accumulating in neurons and astrocytes around small blood vessels at the depths of cortical sulci, especially in frontal and temporal cortex. The topographical pattern — sulcal depths and perivascular — is what distinguishes CTE tau from the diffuse cortical tau of Alzheimer’s. The biochemistry of CTE tau is distinct from PSP, corticobasal degeneration and Pick’s disease tauopathies. Dihexa has no demonstrated effect on tau phosphorylation, tau aggregation, or tau clearance. Drugs that have failed in the AD tauopathy space include gosuranemab, tilavonemab, semorinemab and several others. The anti-tau strategy in CTE has not produced any positive clinical trial.

2. Blood-Brain Barrier (BBB) Leakage

Repetitive head impact causes repeated transient opening of the BBB, with leakage of plasma proteins (fibrinogen, albumin) into the brain parenchyma. Chronic, low-grade BBB leakage has been hypothesised as both a cause and a consequence of CTE perivascular pathology. In 2026, the use of dynamic contrast-enhanced MRI to detect leaky blood-brain barrier in living patients has been proposed as an early warning sign for CTE development in patients with substantial RHI exposure. The HGF/c-Met pathway is genuinely interesting here: HGF stabilises endothelial junctions, promotes pericyte function, and has been shown in stroke models to reduce BBB leakage. This is one of the few CTE biological axes where the Dihexa rationale is more than purely speculative.

3. Chronic Microglial Activation and Neuroinflammation

Post-mortem and TSPO-PET imaging studies show persistent microglial activation in regions affected by CTE pathology, sometimes persisting decades after exposure ends. The microglial phenotype shifts toward chronically pro-inflammatory states, with secretion of IL-1β, TNF-α, and complement factors that drive synaptic stripping. HGF / c-Met activation has been shown in preclinical models to repolarise microglia toward reparative phenotypes, which is a plausible mechanism by which Dihexa could modulate the inflammatory axis of CTE, were a trial ever conducted.

4. Synaptic Loss and White-Matter Degeneration

Independent of tau, CTE produces progressive loss of synapses and cortical thinning, particularly in frontal regions. White-matter degeneration is consistent with the chronic diffuse axonal injury that follows repetitive impact. Synaptogenesis — the explicit Dihexa mechanism — is the obvious counter to this, but synaptic regeneration in a brain still accumulating tau in an unstable connectivity framework is biologically more complex than “more synapses must be better”.

The full molecular detail of the HGF/c-Met pathway and its synaptogenic action is covered in the dedicated mechanism of action guide and the Dihexa vs BDNF review, which clarifies what the famous “10 million times more potent than BDNF” figure actually measures.

Where Could Dihexa Theoretically Fit in CTE Biology?

To be fair to the question, here is the honest mechanistic case for Dihexa in CTE, mapped against the four pathological axes above:

The summary is that Dihexa could, in principle, address three of the four CTE pathology axes — but it cannot address the one that is universally agreed to be the defining and driving lesion. Promoting synaptogenesis and BBB repair in a brain that is still accumulating perivascular p-tau is the equivalent of repainting a building while its foundations continue to subside. It might transiently improve appearance; it does not address the disease.

This is why the fosgonimeton (ATH-1017) clinical experience matters. Fosgonimeton is the closest HGF-pathway molecule to enter pivotal clinical trials. It was tested in Alzheimer’s disease — another tauopathy — and reported mixed Phase 2/3 results. Crucially, fosgonimeton was never tested in CTE.

Direct Dihexa Evidence in CTE: A Single, Unambiguous Answer

At the time of writing (May 2026), there is zero human clinical trial evidence of Dihexa in any CTE-related population: not in former contact-sport athletes, not in military veterans with blast exposure, not in retired boxers, not in suspected TES, not in autopsy-confirmed CTE. No published rodent study has tested Dihexa specifically in an RHI / sub-concussive impact model. The mechanistic case rests on:

• Dihexa’s performance in rodent cognitive-deficit models (scopolamine, aged-rat, Morris water maze, novel object recognition) reviewed in research and studies;
• HGF/c-Met or angiotensin IV activity in unrelated injury models (ischaemic stroke MCAO, controlled cortical impact TBI), discussed in the Dihexa for TBI & Concussion review;
• Mechanistic plausibility on three of the four CTE pathology axes above.

None of those evidence streams constitutes evidence that Dihexa will modify CTE outcomes in humans. Anyone selling Dihexa as a CTE treatment in 2026 is making a claim that the published literature does not support.

The UK Rugby Brain Injury Group Action: Why It Matters for the Field

The active group litigation against UK rugby’s governing bodies is the most significant external pressure on the CTE field outside the United States, and a brief summary helps anyone reading this article from the UK rugby community understand the context.

According to the law firms acting for the claimants (notably Rylands Garth) and reporting in the UK rugby press, more than 1,100 former players from rugby union and rugby league are pursuing a group action against World Rugby, the Rugby Football Union (RFU), the Welsh Rugby Union (WRU) and the Rugby Football League (RFL). The claim alleges that the governing bodies failed to adequately protect players from the risks of head injury and that, as a consequence, the claimants suffer from neurological conditions including dementia, Parkinson’s disease and motor neurone disease.

Notable claimants include members of England’s 2003 Rugby World Cup-winning squad — Steve Thompson, Mark Regan and Phil Vickery — alongside former Wales internationals Gavin Henson, Colin Charvis and Ryan Jones, and former England and British & Irish Lions scrum-half Harry Ellis. The case was next scheduled for review in March 2026. All the governing bodies deny liability. The Solicitors Regulation Authority is separately investigating Rylands Garth following claims by one former player that he was pressured to join the action despite an independent diagnosis showing no evidence of brain injury — a useful reminder that this is contested ground.

The legal action is not, in itself, scientific evidence. What it does do is force three changes that are relevant to anyone evaluating CTE therapies:

• It is mobilising UK research funding into CTE biomarkers and longitudinal cohorts.
• It is creating an identifiable population that may eventually be eligible for prevention or intervention trials — the same population in which Dihexa is sometimes informally discussed.
• It is generating pressure for World Rugby and other federations to fund head-impact-exposure research, with the new Brain Health Service for elite players launched by World Rugby in collaboration with the Drake Foundation and the University of South Wales.

For other affected populations, see the Dihexa for PTSD & Complex PTSD review, which covers the parallel NHS Op COURAGE veterans pathway, the King’s Centre for Military Health Research data on combat-related PTSD-TBI overlap, and the fear-extinction biology relevant to the mood-behavioural early phase of CTE.

CTE Biomarkers in 2026: NfL, p-Tau, BBB MRI and Spatial Transcriptomics

The defining problem of the CTE field is the absence of a validated in-vivo biomarker. Without one, no rigorous interventional trial — for Dihexa or anything else — can be designed. Active biomarker research includes:

Neurofilament Light Chain (NfL)

NfL is a structural axonal protein released into the cerebrospinal fluid and blood after any neuronal injury. It is elevated acutely after concussion, persistently elevated in some former contact-sport athletes, and rises with progression in many neurodegenerative diseases. NfL is not specific for CTE — it cannot distinguish CTE from Alzheimer’s, ALS, MS, vascular dementia, or chronic axonal injury from any cause — but it provides a useful general index of ongoing neurodegeneration that may be incorporated into a future composite biomarker.

Plasma p-Tau (p-tau-181, p-tau-217, p-tau-231)

The maturation of plasma phosphorylated tau assays has transformed Alzheimer’s diagnostics in 2025-2026. p-tau-217 in particular has now been validated as a clinically useful Alzheimer’s pathology biomarker, with accuracy approaching CSF and PET measures and with FDA-cleared and CE-marked commercial assays available. Its specificity for CTE p-tau is unclear: CTE tau is biochemically distinct from AD tau, and current p-tau assays were developed against AD-typical epitopes. The integration of p-tau biomarkers into a CTE diagnostic framework is an active area of research.

Dynamic Contrast-Enhanced MRI of BBB Leakage

A 2026 research direction uses dynamic contrast-enhanced MRI to detect chronic, low-grade blood-brain barrier leakage in living patients with substantial RHI exposure. The proposal is that BBB leakage is an early warning sign for CTE development. This is the imaging axis most directly relevant to the Dihexa mechanistic case, because HGF stabilises endothelial junctions.

Spatially Resolved Transcriptomics

A 2025 bioRxiv pre-print applied spatially resolved transcriptomics to autopsy CTE tissue, identifying a unique molecular disease signature distinct from Alzheimer’s and from normal ageing. This is a research-grade tool that may eventually yield a candidate set of CSF or plasma proteomic biomarkers, but is not currently a clinical assay.

Emerging Clinical Trials

The University of California San Francisco Brain Injury Clinical Trials programme is running multiple 2026 protocols studying blood-based and imaging biomarkers of neuroinflammation in conditions including CTE. The Boston University DIAGNOSE-CTE programme and the US Department of Veterans Affairs LIMBIC-CENC consortium remain the principal multi-site longitudinal cohorts. None of these protocols are testing Dihexa.

Comparative Analogues: What the HGF-Pathway Drug Class Has Actually Done in Tauopathies

The most informative empirical analogue for “what should we expect Dihexa to do in CTE” is the closely-related clinical compound fosgonimeton (ATH-1017) developed by Athira Pharma. Fosgonimeton is a small molecule that enhances HGF/c-Met signalling and is therefore mechanistically adjacent to Dihexa. It was tested in:

• Alzheimer’s disease (LIFT-AD Phase 2/3, ACT-AD Phase 2): mixed signal, with topline reads that did not meet primary endpoints in most analyses but generated downstream biomarker discussion.
• Parkinson’s disease dementia & dementia with Lewy bodies (SHAPE Phase 2): signal of interest, no Phase 3 yet.
• CTE: never tested.

The lesson from fosgonimeton is informative but cautionary. Even with full pharmaceutical development — properly designed protocols, validated cognitive endpoints, biomarker arms, regulatory engagement — an HGF enhancer in an established tauopathy did not produce a clear, replicated efficacy signal. There is no reason to expect that an unregulated research-chemical version of similar mechanism, used at unvalidated doses, would do better in a more complex tauopathy (CTE) with no diagnostic certainty.

For the broader context of HGF/c-Met clinical translation across neurological indications, see Dihexa & Alzheimer’s Research, Dihexa for Multiple Sclerosis (remyelination biology), Dihexa for ALS & MND (motor neuron protection), and the Dihexa for Stroke Recovery & PSCI review.

Specific Risks of Dihexa Use in the CTE-At-Risk Population

The standard Dihexa side-effects and risks profile applies in this population, with several specific amplifications that anyone in the CTE-at-risk group should consider:

• Theoretical oncogenicity: sustained c-Met activation is associated with several human cancers (renal, gastric, lung, hepatocellular). The brain after RHI has chronically activated cell-cycle pathways. Long-term Dihexa use in this context has no safety data.
• Compromised blood-brain barrier: a brain with chronic low-grade BBB leakage will have altered CNS exposure to any administered peptide; unpredictable dose-response is the rule, not the exception.
• Mood and behavioural instability: the early phase of CTE is dominated by depression, impulsivity and suicidality. The mood effects of unregulated peptides — whether of Dihexa itself or of contaminants common in unregulated peptide supply — are unpredictable and potentially severe in this vulnerable population.
• Self-monitoring failure: cognitive impairment makes accurate self-monitoring of side effects and dose unreliable.
• Polypharmacy: many former athletes are on multiple medications (analgesics, antidepressants, beta-blockers, hypertension agents). Dihexa pharmacokinetics and interaction profile in humans is unstudied.
• Drug supply contamination: the UK research-chemical market for peptides has documented contamination, mis-labelling and adulteration problems; see the UK research chemicals page for the regulatory context.

The combination of biological vulnerability and decisional vulnerability in the post-RHI population is the single strongest argument for not self-experimenting with research peptides in this group. See the dosage page and the UK legal status page for the full regulatory framing.

What Actually Helps Someone Worried About CTE in the UK in 2026

Because there is no disease-modifying therapy for CTE in 2026, the evidence-based approach is to (a) confirm or refute alternative diagnoses, (b) treat modifiable contributors to cognitive and behavioural decline, and (c) participate in research if possible. Practical UK steps:

1. Speak to your GP about referral to NHS cognitive neurology. Reversible causes of cognitive change need to be excluded first (B12, thyroid, depression, obstructive sleep apnoea, medication, alcohol). NICE guideline NG97 governs the dementia diagnostic pathway.
2. If you are a former or current professional athlete, ask about the appropriate sports concussion service. The Imperial College London Sport Concussion Service is one option; World Rugby’s Brain Health Service for elite players opened in 2025 in collaboration with the Drake Foundation and the University of South Wales.
3. If you are a UK military veteran with blast exposure or repeated TBI history, the NHS Op COURAGE service is the appropriate first-line pathway. Combat Stress and Forces in Mind Trust provide adjacent support.
4. Address modifiable cardiovascular dementia risk factors. The 2024 Lancet Commission identifies 14 modifiable factors covering 45% of dementia cases. Hypertension, LDL cholesterol, type-2 diabetes, smoking, obesity, alcohol, hearing loss, vision loss and social isolation are particularly relevant in the former athlete population. See the Dihexa for Vascular Dementia review.
5. Optimise sleep. Disrupted sleep accelerates p-tau accumulation. See the Dihexa, sleep and memory consolidation review.
6. Treat depression and anxiety properly. The depression-CTE mortality link is not negligible. See the Dihexa for Depression & Mood review and the Dihexa for Anxiety & Chronic Stress review.
7. Get a structured exercise plan. Aerobic exercise has the strongest evidence base of any single intervention for reducing dementia risk and improving cognitive outcomes after brain injury.
8. Consider participation in research. The UK NIHR Be Part of Research portal, the Join Dementia Research registry, and the UK Brain Bank Network all welcome registrants from RHI-exposed populations.
9. For support and information, contact Headway — the brain injury association and the Brain Injury Group’s rugby and CTE resource.

For the broader evidence-based framework on how cognitive change after brain injury maps onto the cognitive ageing trajectory, see the Dihexa for MCI & Brain Aging review and cognitive enhancement page.

The Bottom Line on Dihexa and CTE in 2026

Selected References & External Sources

1. Alosco ML et al. (2026). Chronic traumatic encephalopathy as a distinct cause of dementia: clinicopathological analysis of 614 brain donors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. — BU Brink summary · EurekAlert release
2. Boston University CTE Center (May 2026). Clinical traumatic encephalopathy syndrome (TES) criteria identify only 24% of autopsy-confirmed CTE. — MedicalXpress coverage
3. McKee AC et al. (2023). The neuropathological diagnosis of chronic traumatic encephalopathy: criteria and relationship to repetitive head impacts. — PMC10020327
4. Stewart W et al. (2023). Risk of chronic traumatic encephalopathy in rugby union is associated with length of playing career. Acta Neuropathologica. — PMC10627955 · University of Glasgow news
5. Stamm JM et al. (2026). Spatially resolved transcriptomics reveals a unique disease signature and potential biomarkers for chronic traumatic encephalopathy. — bioRxiv pre-print
6. Belson K et al. (2018). Imperial College London. Dementia is rare in midlife rugby players, but long-term risk may be increased. — Imperial News
7. Concussion Legacy Foundation (January 2026 update). CTE Fact Sheet. — PDF
8. UCSF Brain Injury Clinical Trials 2026 programme — UCSF
9. Benoist CC et al. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. — PubMed 24403718
10. Wright JW & Harding JW (2015). The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. — PubMed 25711386
11. Boston University CTE Center — bu.edu/cte
12. Headway — the UK brain injury association — headway.org.uk
13. Drake Foundation — head injury research — drakefoundation.org
14. NIHR Be Part of Research portal — bepartofresearch.nihr.ac.uk
15. NHS Op COURAGE veterans mental-health services — NHS Op COURAGE
16. UK Government — concussion in grassroots sport guidance — gov.uk